Form 4: Boundless Bio CEO Hornby Reprices Stock Options

Boundless Bio CEO Zachary Hornby repriced several stock option grants on August 19, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 19, 2024, Zachary Hornby, the President and CEO of Boundless Bio, Inc., repriced several stock option grants.
• The repriced options include 256,410 options originally vesting from July 7, 2021, 471,282 options originally vesting from July 13, 2023, 257,207 options originally vesting from March 15, 2024 and 162,343 options originally vesting from April 27, 2024.
• The new exercise price for all the repriced options is $3.56 per share, representing the fair market value on the repricing date.
• A clause exists where the exercise price reverts to the original price if the options are exercised or employment is terminated before a 'premium end date' unless it's a 'qualifying termination'.
• The 'premium end date' is the earliest of August 19, 2026, a change in control, or a qualifying termination (involuntary termination due to reduction in force or termination due to death or disability).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports a transaction. The repricing itself could be viewed as either positive (re-incentivizing management) or negative (lack of confidence in future stock price growth), depending on the investor's perspective.

Positives

• The repricing aligns the option exercise price with the current fair market value, potentially incentivizing the CEO.
• The clause that reverts the exercise price to the original price under certain conditions protects the company from potential losses if the CEO leaves before a certain date.

Negatives

• The repricing of options could be seen negatively by shareholders if it's perceived as rewarding poor performance or a lack of confidence in future stock price appreciation.
• The complex terms of the repricing, including the 'premium end date' and 'qualifying termination' definitions, could be confusing for investors.

Risks

• The possibility of the exercise price reverting to the original price if the CEO's employment is terminated under certain circumstances before August 19, 2026, could create uncertainty.
• The repricing could be scrutinized by shareholders and proxy advisory firms, potentially leading to negative publicity.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the repriced options.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has fallen below the option's exercise price. It's common in the biotech industry, which can be volatile and subject to long development timelines.

Comparison to Industry Standards

• Repricing of stock options is a fairly common practice in the biotech industry, especially for companies that have experienced a significant decline in their stock price.
• Companies like Novavax and Ocugen have also repriced options in the past to retain and motivate key employees.
• The specific terms of the repricing, such as the 'premium end date' and 'qualifying termination' clauses, are company-specific and designed to align with the company's goals and circumstances.

Stakeholder Impact

• Shareholders may have mixed reactions depending on their view of the company's performance and the fairness of the executive compensation.
• Employees holding stock options may be positively impacted by the lower exercise price.
• The repricing has no direct impact on customers, suppliers, or creditors.

Key Dates